Objectives: To evaluate the efficacy of alteration from gonadotropin-releasing hormone (GnRH) agonist to antagonist in patients with castration-resistant prostate cancer (CRPC). Methods: Fourteen patients with CRPC were switched from GnRH agonist to GnRH antagonist. CRPC was defined as 3 consecutive rises of PSA values under androgen deprivation therapy despite a testosterone level at the castr...

BACKGROUND Copeptin (pre-proAVP) secreted in equimolar amounts with vasopressin closely reflects vasopressin release. Copeptin has been shown to subtly mirror stress potentially mediated via corticotrophin-releasing hormone. To further test a potential direct interaction of corticotrophin-releasing hormone with copeptin release, which could augment vasopressin effects on pituitary function, we ...

“Ovaprim-C” manufactured by a Canada-based company, M/s Syndel laboratories, is in use world over today for induced spawning of fishes. Ovaprim-C contains 20 μg of Salmon gonadotropin releasing hormone (GnRH) and 10 mg of domperidone ml. The high cost and viscosity of Ovaprim proved a prohibitive factor. Another synthetic hormone “Ovatide” has been manufactured by a Mumbay based M/s Hemmo Pharm...

BACKGROUND In Spanish public hospital Reproduction Units it is very problematic to perform programmed intrauterine insemination (IUI) on weekends, if indicated. Small previous pilot studies suggest that using a GnRH antagonist to avoid an LH weekend surge would allow to perform IUI on the following Monday, not impairing the expected pregnancy rate. METHODS Between 1st January 2007 and 31st De...

BACKGROUND The goal of this study was to assess the association between endometrial thickness on the chorionic gonadotropin (hCG) day and in vitro fertilization and embryo transfer (IVF-ET) outcome in normal responders after GnRH antagonist administration. METHODS A retrospective cohort study was performed in normal responders with GnRH antagonist administration from January 2011-December 201...

BACKGROUND This randomized controlled trial was designed to assess the impact of oral contraceptive (OC) scheduling with a GnRH antagonist (ganirelix) regimen on the ovarian response of women undergoing recombinant FSH (rFSH) stimulation for IVF, compared with a non-scheduled ganirelix regimen and a long GnRH agonist (nafarelin) protocol. METHODS A total of 110 women was treated with an OC an...